ClinicalTrials.Veeva

Menu
F

Fred Hutchinson Cancer Research Center | Seattle, WA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Carboplatin
Paclitaxel
Atezolizumab
Bevacizumab
Lenalidomide
Cisplatin
Ramucirumab
Ibrutinib
Nivolumab
Crizotinib

Parent organization

This site is a part of Fred Hutchinson Cancer Research Center

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

30 of 108 total trials
Locations recently updated

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation...

Enrolling
Waldenström Macroglobulinemia
Marginal Zone Lymphoma
Drug: BGB-16673

An Open-Label and Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of...

Active, not recruiting
Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Vancomycin Pre-Treatment
Drug: SER-155

A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-...

Active, not recruiting
Hiv
Biological: Core-g28v2 60mer mRNA Vaccine
Biological: eOD-GT8 60mer mRNA Vaccine

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) thera...

Enrolling
Post-essential Thrombocythemia Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Drug: Physician's Choice medications
Drug: Pacritinib

This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in partici...

Active, not recruiting
Lymphocytic Leukemia, Chronic
Lymphoma, Non Hodgkin
Drug: BTCT4465A (Mosunetuzumab) IV
Drug: BTCT4465A (Mosunetuzumab) SC

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP)...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Talquetamab
Drug: Dexamethasone

This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig alone or in combination with tiragolumab compared with atezolizuma...

Enrolling
Urothelial Cancer
Drug: Tiragolumab
Drug: Atezolizumab
Locations recently updated

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Drug: Venetoclax
Drug: Azacitidine

This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or...

Active, not recruiting
Chronic Graft-versus-host-disease
Drug: Axatilimab

BDTX-4933-101 is a first-in-human, open-label, Phase 1 dose escalation and an expansion cohort study designed to evaluate the safety and tolerability...

Enrolling
Colorectal Carcinoma
KRAS G12V
Drug: BDTX-4933

The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with tem...

Enrolling
Astrocytoma, Grade III
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Drug: Debio 0123
Drug: Temozolomide
Locations recently updated

This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGV...

Enrolling
aGVHD
Graft Versus Host Disease
Drug: EQ001 Placebo
Biological: Itolizumab

The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorour...

Enrolling
Adenocarcinoma, Pancreatic Ductal
Drug: mFOLFIRINOX
Drug: Autogene cevumeran

This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of intravenous (IV) or subcutaneous (SC) mosunetu...

Active, not recruiting
B-cell Non-Hodgkin Lymphoma
Drug: Polatuzumab vedotin
Drug: Tocilizumab

This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD.The study duration for a participant...

Enrolling
Chronic Graft Versus Host Disease
Drug: Prednisone
Drug: Prednisolone

The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for who...

Enrolling
Neoplasm Metastasis
Non-Small Cell Lung Cancer
Drug: zongertinib
Locations recently updated

This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human leukocyte...

Enrolling
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Drug: Mylotarg
Biological: VOR33

This study is open to adults with a type of cancer called dedifferentiated liposarcoma (DDLPS). They can join the study if their tumours are positive...

Enrolling
Liposarcoma, Dedifferentiated
Drug: Brigimadlin

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with adva...

Enrolling
Metastatic Cancer
Advanced Cancer
Drug: Cetuximab
Drug: Afatinib

This is a trial of Regorafenib in combination with pembrolizumab for patients with MSI-H colorectal cancer consisting of lead-in phase examining prel...

Enrolling
MSI-H Colorectal Cancer
Drug: Regorafenib
Drug: Pembrolizumab

Trial sponsors

National Cancer Institute (NCI) logo
SWOG Cancer Research Network logo
ECOG-ACRIN Cancer Research Group logo
A
BeiGene logo
Memorial Sloan Kettering Cancer Center (MSK) logo
Boehringer Ingelheim logo
Genentech logo
Incyte logo
NRG Oncology logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems